ACXP
Income statement / Annual
Last year (2024), Acurx Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Acurx Pharmaceuticals, Inc.'s net income was -$14.10 B.
See Acurx Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.40 M
|
$6.04 M
|
$4.75 M
|
$2.03 M
|
$2.20 M
|
$3.51 M
|
| General & Administrative Expenses |
$8.70 B
|
$8.53 M
|
$7.34 M
|
$10.78 M
|
$2.40 M
|
$2.42 M
|
| Selling & Marketing Expenses |
-$8.69 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.70 M
|
$8.53 M
|
$7.34 M
|
$10.78 M
|
$2.40 M
|
$2.42 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.10 M
|
$14.58 M
|
$12.09 M
|
$12.81 M
|
$4.60 M
|
$5.93 M
|
| Cost And Expenses |
$14.10 M
|
$14.58 M
|
$12.09 M
|
$12.81 M
|
$4.60 M
|
$5.93 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$14.58 M
|
$12.09 M
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$14.10 M |
-$14.58 M |
-$12.09 M |
-$12.75 M |
-$4.60 M |
-$5.93 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$0.00
|
$0.00
|
$66.50 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$14.10 M
|
-$14.58 M
|
-$12.09 M
|
-$12.75 M
|
-$4.60 M
|
-$5.93 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.22 K
|
-$66.50 K
|
$0.00
|
$0.00
|
| Net Income |
-$14.10 B
|
-$14.58 M
|
-$12.09 M
|
-$12.75 M
|
-$4.60 M
|
-$5.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-17450.8 |
-23.01 |
-22.36 |
-24.96 |
-9.28 |
-12 |
| EPS Diluted |
-17450.8 |
-23.01 |
-22.36 |
-24.96 |
-9.28 |
-12 |
| Weighted Average Shares Out |
$808.15 K
|
$633.60 K
|
$540.80 K
|
$510.80 K
|
$495.80 K
|
$375.10 K
|
| Weighted Average Shares Out Diluted |
$808.15 K
|
$633.60 K
|
$540.80 K
|
$510.80 K
|
$495.80 K
|
$477.05 K
|
| Link |
|
|
|
|
|
|
